Key Points
- CEO Amit Kumar purchased 5,000 Anixa Biosciences shares at an average price of $2.76, investing $13,800 and increasing his holdings to 662,000 shares.
- The purchase follows several insider acquisitions by Kumar since July, suggesting continued insider buying despite the stock trading near the lower end of its 52-week range.
- ANIX reported a quarterly loss of $0.08 per share, in line with estimates. Analysts have a consensus “Hold” rating and a $10.00 price target, while institutional investors own 29.13% of the company.
Anixa Biosciences Inc (NASDAQ:ANIX - Get Free Report) CEO Amit Kumar bought 5,000 shares of the stock in a transaction on Thursday, September 10th. The stock was purchased at an average cost of $2.76 per share, with a total value of $13,800.00. Following the acquisition, the chief executive officer owned 662,000 shares in the company, valued at approximately $1,827,120. This represents a 0.76% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.
Amit Kumar also recently made the following trade(s):
- On Friday, July 31st, Amit Kumar purchased 5,000 shares of Anixa Biosciences stock. The shares were purchased at an average cost of $3.47 per share, for a total transaction of $17,350.00.
- On Friday, July 24th, Amit Kumar purchased 3,000 shares of Anixa Biosciences stock. The shares were purchased at an average price of $3.73 per share, for a total transaction of $11,190.00.
- On Monday, July 20th, Amit Kumar acquired 5,000 shares of Anixa Biosciences stock. The stock was purchased at an average cost of $3.46 per share, with a total value of $17,300.00.
- On Monday, July 27th, Amit Kumar acquired 3,188 shares of Anixa Biosciences stock. The stock was purchased at an average cost of $3.37 per share, with a total value of $10,743.56.
- On Monday, July 27th, Amit Kumar acquired 5,000 shares of Anixa Biosciences stock. The stock was acquired at an average price of $3.44 per share, with a total value of $17,200.00.
- On Friday, July 10th, Amit Kumar bought 5,000 shares of Anixa Biosciences stock. The shares were acquired at an average price of $3.04 per share, for a total transaction of $15,200.00.
Anixa Biosciences Price Performance
ANIX opened at $2.76 on Friday. Anixa Biosciences Inc has a fifty-two week low of $2.32 and a fifty-two week high of $5.46. The firm has a market capitalization of $93.90 million, a price-to-earnings ratio of -8.62 and a beta of 0.51. The company's 50 day moving average price is $3.33 and its two-hundred day moving average price is $2.98.
Anixa Biosciences (NASDAQ:ANIX - Get Free Report) last announced its quarterly earnings results on Wednesday, September 9th. The company reported ($0.08) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.08). As a group, equities research analysts predict that Anixa Biosciences Inc will post -0.31 EPS for the current year.
Hedge Funds Weigh In On Anixa Biosciences
Hedge funds and other institutional investors have recently bought and sold shares of the company. Integrated Wealth Concepts LLC bought a new stake in Anixa Biosciences during the second quarter valued at $30,000. Corient Private Wealth LP raised its position in shares of Anixa Biosciences by 87.0% in the 2nd quarter. Corient Private Wealth LP now owns 37,400 shares of the company's stock worth $105,000 after acquiring an additional 17,400 shares in the last quarter. AXQ Capital LP bought a new position in shares of Anixa Biosciences in the 2nd quarter worth about $41,000. Canada Pension Plan Investment Board acquired a new position in shares of Anixa Biosciences in the 2nd quarter valued at about $38,000. Finally, Sanctuary Advisors LLC acquired a new position in shares of Anixa Biosciences in the 2nd quarter valued at about $29,000. Institutional investors and hedge funds own 29.13% of the company's stock.
Wall Street Analyst Weigh In
Several research analysts recently issued reports on the company. Citigroup reaffirmed a "buy" rating on shares of Anixa Biosciences in a research report on Friday, June 12th. Zacks Research lowered Anixa Biosciences from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, August 19th. HC Wainwright reissued a "buy" rating on shares of Anixa Biosciences in a research note on Friday, June 12th. D. Boral Capital restated a "buy" rating and set a $10.00 price objective on shares of Anixa Biosciences in a research report on Tuesday, June 30th. Finally, Weiss Ratings lowered Anixa Biosciences from a "sell (d-)" rating to a "sell (e+)" rating in a research note on Thursday, September 3rd. Three research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, Anixa Biosciences has a consensus rating of "Hold" and a consensus target price of $10.00.
Check Out Our Latest Stock Analysis on Anixa Biosciences
About Anixa Biosciences
(
Get Free Report)
Anixa Biosciences is a clinical-stage immuno-oncology and infectious disease company developing novel cell-based immunotherapies and vaccine platforms. Through its Anixa Therapeutics division, the company is advancing antibody and T-cell modalities, including an ovarian cancer immunotherapy candidate and a COVID-19 vaccine leveraging a proprietary virus-like particle (VLP) technology. Its research pipeline emphasizes modular vaccine design and personalized cancer cell therapy aimed at inducing durable immune responses against solid tumors.
In parallel, Anixa Diagnostics is developing the ADAPT diagnostic platform, a high-throughput proteomics approach using engineered peptides derived from spider venom.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
